BGM
BGM Group Ltd.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · CN
$0.29
+0.71%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 76.5M | 37.9M | 25.1M | 46.5M | 64.9M |
| Cost of Revenue | 66.3M | 33.1M | 21.0M | 44.7M | 58.6M |
| Gross Profit | 10.3M | 4.8M | 4.1M | 1.8M | 6.2M |
| Operating Expenses | |||||
| R&D Expense | 1.4M | 672.7K | 1.4M | 568.5K | 1.2M |
| SG&A Expense | 24.5M | 16.8M | 3.3M | 3.8M | 2.9M |
| General & Admin Expense | 5.4M | — | 2.7M | 2.8M | 2.1M |
| Selling & Marketing Expense | 451.1K | — | 592.8K | 961.7K | 751.4K |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 26.0M | 17.4M | 4.7M | 4.4M | 4.1M |
| Cost and Expenses | 92.2M | 50.5M | 25.7M | 49.1M | 62.8M |
| Operating Income (EBIT) | (15.7M) | (12.6M) | (563.8K) | (2.6M) | 2.1M |
| Non-Operating | |||||
| Interest Income | 101.9K | 83.1K | — | 99.2K | 24.9K |
| Interest Expense | 11.3K | — | 639.5K | — | — |
| Net Interest Income | 90.6K | 83.1K | (639.5K) | 99.2K | 24.9K |
| Other Non-Op Income/Expense | (11.3M) | (7.4M) | (1.6M) | (5.3M) | (541.4K) |
| Non-Operating Income (excl Interest) | 2.9M | — | (206.4K) | (192.4K) | (413.7K) |
| EBT (Pre-Tax Income) | (27.0M) | (19.9M) | (2.1M) | (7.9M) | 1.6M |
| Income Tax Expense | (3.8M) | 277.8K | (620.0K) | 219.2K | 194.3K |
| Bottom Line | |||||
| Net Income | (22.9M) | (19.9M) | (1.4M) | (7.8M) | 1.1M |
| Earnings from Cont. Ops | (23.3M) | (20.2M) | (1.5M) | (8.1M) | 1.4M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (22.9M) | (19.9M) | (1.4M) | (7.8M) | 1.1M |
| Per Share | |||||
| Basic EPS | ($0.19) | ($0.18) | ($0.20) | ($1.08) | $0.15 |
| Diluted EPS | ($0.22) | ($0.18) | ($0.20) | ($1.08) | $0.15 |
| Revenue Per Share | $0.41 | $0.33 | $3.47 | $6.43 | $8.97 |
| Shares | |||||
| Basic Shares Outstanding | 185.6M | 113.3M | 7.2M | 7.2M | 7.2M |
| Diluted Shares Outstanding | 185.6M | 113.3M | 7.2M | 7.2M | 7.2M |
| Profitability Metrics | |||||
| EBITDA | (15.7M) | (11.1M) | 879.9K | (1.3M) | 3.7M |
| D&A | 2.9M | 1.5M | 1.2M | 1.1M | 1.2M |
| EBIT | (18.6M) | (12.6M) | (357.4K) | (2.4M) | 2.5M |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026